D-Wave Quantum falls nearly 3% as earnings miss overshadows revenue beat
On Thursday, JPMorgan initiated coverage on Mereo BioPharma Group (NASDAQ:MREO) with an Overweight rating, accompanied by a price target of $7.00. The stock, currently trading at $2.37, has seen a significant decline of 32% year-to-date and is trading near its 52-week low, according to InvestingPro data. The positive outlook is based on the anticipation of data readouts from the company’s phase 3 trials of setrusumab, a treatment for osteogenesis imperfecta (OI), which are expected to provide significant results.
The trials, named ORBIT and COSMIC, are conducted in partnership with Ultragenyx (NASDAQ:RARE), a company also under JPMorgan’s coverage. The analyst expressed a "strong conviction in success" for the upcoming second interim analysis, anticipated for mid-2025, or the final analysis in the fourth quarter of 2025. With a strong current ratio of 5.4 and minimal debt, InvestingPro data shows Mereo is well-positioned financially to support these crucial trials.
Mereo’s valuation is considered attractive, especially as the company approaches these critical data readouts. The phase 2 data has already demonstrated a positive and statistically significant impact of setrusumab on patients with Types I, III, and IV OI, which comprises the patient population of the ongoing phase 3 trials.
The feedback from key opinion leaders has been supportive, further bolstering confidence in the potential success of the phase 3 trials. Should the ORBIT trial yield positive results, which is leading from a regulatory perspective, setrusumab is poised to meet a significant unmet need in the OI patient community.
In terms of market potential, JPMorgan foresees rapid adoption of setrusumab in the European Union. The firm also identifies peak penetration and pricing as potential additional upside factors for Mereo BioPharma’s stock. With a market cap of $367 million and analysts setting targets as high as $10.01, the stock shows significant potential upside. Discover more detailed analysis and 10+ additional ProTips for MREO with a subscription to InvestingPro, including comprehensive Fair Value analysis and financial health scores.
In other recent news, Mereo BioPharma Group has been the focus of analyst discussions and investor interest due to its ongoing clinical trials and financial outlook. BTIG analysts have maintained a Buy rating on Mereo BioPharma, citing the potential of setrusumab, their investigational treatment for osteogenesis imperfecta (OI), which is in Phase 3 trials. They have expressed a high probability of success for the drug, anticipating significant milestones in 2025. Mereo BioPharma ended the fiscal year 2024 with $69.8 million in cash, expected to support operations into 2027.
Cantor Fitzgerald analysts have also maintained an Overweight rating and a $7.00 price target for Mereo BioPharma, highlighting the drug’s potential to significantly reduce fractures. They noted that even if the IA2 trial does not meet its primary endpoint, the drug could still be considered clinically meaningful. Additionally, insights from a webinar with the Osteogenesis Imperfecta Foundation have underscored the importance of setrusumab’s development, with Cantor Fitzgerald maintaining a positive outlook on the collaboration between Mereo BioPharma and Ultragenyx.
The anticipated second interim analysis of setrusumab in mid-2025 is seen as a crucial milestone. The collaboration aims to address the needs of the OI community, with the potential for the treatment to become a significant addition if approved. As these developments unfold, investors and stakeholders continue to monitor Mereo BioPharma’s progress closely.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.